Unknown

Dataset Information

0

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.


ABSTRACT:

Background

Taxanes such as paclitaxel and docetaxel are used successfully to treat breast cancer, usually in combination with other agents. They interfere with microtubules causing cell cycle arrest; however, the mechanisms underlying the clinical effects of taxanes are yet to be fully elucidated.

Methods

Isogenic paclitaxel resistant (PACR) MDA‒MB‒231, paclitaxel resistant ZR75‒1 and docetaxel resistant (DOCR) ZR75‒1 cell lines were generated by incrementally increasing taxane dose in native cell lines in vitro. We used aCGH analysis to identify mechanisms driving taxane resistance.

Results

Taxane resistant cell lines exhibited an 18-170 fold increased resistance to taxanes, with the ZR75-1 resistant cell lines also demonstrating cross resistance to anthracyclines. Paclitaxel treatment of native cells resulted in a G2/M block and a decrease in the G1 phase of the cell cycle. However, in the resistant cell lines, minimal changes were present. Functional network analysis revealed that the mitotic prometaphase was lost in the resistant cell lines.

Conclusion

This study established a model system for examining taxane resistance and demonstrated that both MDR and mitosis represent common mechanism of taxane resistance.

SUBMITTER: Kenicer J 

PROVIDER: S-EPMC4203938 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.

Kenicer Juliet J   Spears Melanie M   Lyttle Nicola N   Taylor Karen J KJ   Liao Linda L   Cunningham Carrie A CA   Lambros Maryou M   MacKay Alan A   Yao Cindy C   Reis-Filho Jorge J   Bartlett John M S JM  

BMC cancer 20141014


<h4>Background</h4>Taxanes such as paclitaxel and docetaxel are used successfully to treat breast cancer, usually in combination with other agents. They interfere with microtubules causing cell cycle arrest; however, the mechanisms underlying the clinical effects of taxanes are yet to be fully elucidated.<h4>Methods</h4>Isogenic paclitaxel resistant (PACR) MDA‒MB‒231, paclitaxel resistant ZR75‒1 and docetaxel resistant (DOCR) ZR75‒1 cell lines were generated by incrementally increasing taxane do  ...[more]

Similar Datasets

| S-EPMC8466451 | biostudies-literature
| S-EPMC9832699 | biostudies-literature
| S-EPMC8448965 | biostudies-literature
| S-EPMC4244604 | biostudies-literature
| S-EPMC6469161 | biostudies-literature
| S-EPMC2666263 | biostudies-literature
| S-EPMC11534953 | biostudies-literature
| S-EPMC3203088 | biostudies-literature
| S-EPMC4361057 | biostudies-literature
| S-EPMC7097144 | biostudies-literature